Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of PF-04965842 on Rosuvastatin Pharmacokinetics in Healthy Participants
NCT03806101Phase 1Completed
- Sponsor
- Pfizer
- Start
- Jan 2019
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of abrocitinib in atopic dermatitis (AD) (2 arms), sponsored by Pfizer. Primary endpoints: Area under the plasma concentration-time curve from zero to infinity at 72 hours and Renal Clearance at 72 hours. Started Jan 2019; status: completed.
02
Drugs
abrocitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03806101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03806101.